Skip to content
The Nexus
DossierENTITY

23andMe Research Institute

Coverage of 23andMe Research Institute in the Nexus archive.

Earliest in view: Apr 16 · 11:00 UTCMost recent: Apr 16 · 11:00 UTC
Co-mentioned in this coverage
GLP-1 receptor agoniststopic1semaglutidetopic1tirzepatidetopic1GLP1R genetopic1GIPR genetopic1Noura Abul-Husnperson1Dr. Peter Balazsperson1
Recent coverage
  • HEALTHApr 16 · 11:00 UTCFOX NEWS
    This could be why your weight-loss medication isn’t delivering results

    A study in Nature found genetic variations in the GLP1R and GIPR genes influence the effectiveness and side effects of GLP-1 receptor agonists like semaglutide and tirzepatide. Patients with specific gene variants experienced modest weight loss boosts and increased nausea risks, highlighting potential for personalized treatment approaches.